Immunogen (IMGN) Announces EU Acceptance of Marketing Authorization Application for Mirvetuximab Soravtansine streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
The European Medicines Agency has accepted a marketing authorization application seeking the approval of mirvetuximab soravtansine-gynx for the treatment of patients with folate receptor alpha–positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Immunogen (IMGN) Announces ELAHERE Shows Overall and PFS Benefit Regardless of Prior PARPi Exposure or Prior Lines of Therapy in FRα-Positive Platinum-Resistant Ovarian Cancer streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Operator: Good morning and welcome to ImmunoGen’s second quarter 2023 financial and operating results conference call. Today’s conference is being recorded.
ImmunoGen, Inc. announced that Anna Berkenblit, MD, Senior Vice President and Chief Medical Officer, is stepping down from her position with the Company to take a
well-deserved professional hiatus.